1997
DOI: 10.1002/(sici)1098-2264(199704)18:4<269::aid-gcc4>3.0.co;2-z
|View full text |Cite
|
Sign up to set email alerts
|

MSH2 andMLH1 mutations in sporadic replication error-positive colorectal carcinoma as assessed by two-dimensional DNA electrophoresis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
12
0

Year Published

1998
1998
1999
1999

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 101 publications
(12 citation statements)
references
References 26 publications
0
12
0
Order By: Relevance
“…This study Risinger et al (1996) Risinger et al (1996 N-MSH6-1F MSH6-1F MSH6-1R Originates from a family meeting the Amsterdam criteria for HNPCC (Vasen et al, 1991); f Loss of heterozygosity observed in tumor (Hemminki et al, 1994;Wu et al, 1997) with`severe' RER (n=33), 22 of which were known to have somatic and/or germline mutations in MSH2 or MLH1 while no mutations in these genes had been identi®ed in 11 (NystroÈ m-Lahti et al, 1996;Wu et al, 1997;Aaltonen et al, 1998) (Figure 1a). Interestingly, the overall mutation rates, expressed as the proportions of mutated loci among all studied MSH3, MSH6, BAX, and TGFb RII loci, varied remarkably between these groups in that`mild' RER tumors showed no mutations at all whereas in tumors with`severe' RER, the rate was signi®cantly higher in those showing MSH2 or MLH1 mutations, compared to the remaining tumors with a similar RER phenotype (46/ 88, 52% vs 11/44, 25%, P=0.005) ( Table 3).…”
Section: Msh3 Msh6 Bax and Tgfb Rii Mutations In`mild' And`severe' mentioning
confidence: 99%
See 2 more Smart Citations
“…This study Risinger et al (1996) Risinger et al (1996 N-MSH6-1F MSH6-1F MSH6-1R Originates from a family meeting the Amsterdam criteria for HNPCC (Vasen et al, 1991); f Loss of heterozygosity observed in tumor (Hemminki et al, 1994;Wu et al, 1997) with`severe' RER (n=33), 22 of which were known to have somatic and/or germline mutations in MSH2 or MLH1 while no mutations in these genes had been identi®ed in 11 (NystroÈ m-Lahti et al, 1996;Wu et al, 1997;Aaltonen et al, 1998) (Figure 1a). Interestingly, the overall mutation rates, expressed as the proportions of mutated loci among all studied MSH3, MSH6, BAX, and TGFb RII loci, varied remarkably between these groups in that`mild' RER tumors showed no mutations at all whereas in tumors with`severe' RER, the rate was signi®cantly higher in those showing MSH2 or MLH1 mutations, compared to the remaining tumors with a similar RER phenotype (46/ 88, 52% vs 11/44, 25%, P=0.005) ( Table 3).…”
Section: Msh3 Msh6 Bax and Tgfb Rii Mutations In`mild' And`severe' mentioning
confidence: 99%
“…Typical RER Thirty-three colorectal tumors were investigated, 22 of which were known to have germline and/or somatic mutations in MSH2 or MLH1, whereas no such mutations had been detected in 11 (Wu et al, 1997;NystroÈ m-Lahti et al, 1996;Aaltonen et al, 1998).…”
Section: Tumor Selectionmentioning
confidence: 99%
See 1 more Smart Citation
“…Among the MMR genes, the hMSH2 or the hMLH1 gene is most frequently mutated in HNPCC patients (Liu et al, 1996;Weber et al, 1997). However, in many types of sporadic cancers hMSH2 or hMLH1 mutation is rare (Herfarth et al, 1997;Kowalski et al, 1997;Liu et al, 1995;Thibodeau et al, 1996;Wu et al, 1997b). Moreover, mutations in MMR genes have no marked hot-spots such as ones in the p53 gene (Beck et al, 1997;Liu et al, 1996;Nystrom-Lahti et al, 1996;Weber et al, 1997) and MMR genes sometimes undergo epigenetic silencing (Ahuja et al, 1997).…”
mentioning
confidence: 99%
“…PCR amplification of RET exons 1 and 4 and a part of MSH6 exon 1 was carried out as previously described (15,16). A 60 bp GC clamp was attached to one of the primers.…”
Section: Dna Amplificationmentioning
confidence: 99%